Patents Assigned to INTELLIA THERAPEUTICS, INC.
  • Lymphocyte Activation Gene 3 (LAG3) Compositions and Methods for Immunotherapy
    Publication number: 20230383253
    Abstract: Compositions and methods for editing, e.g., altering a DNA sequence, within a LAG3 gene are provided. Compositions and methods for immunotherapy are provided.
    Type: Application
    Filed: August 7, 2023
    Publication date: November 30, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventor: Danielle Ryan Cook
  • Natural Killer Cell Receptor 2B4 Compositions and Methods for Immunotherapy
    Publication number: 20230383252
    Abstract: Compositions and methods for editing, e.g., altering a DNA sequence, within a 2B4 gene are provided. Compositions and methods for immunotherapy are provided.
    Type: Application
    Filed: August 7, 2023
    Publication date: November 30, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventor: Danielle Ryan Cook
  • T-Cell Immunoglobulin and Mucin Domain 3 (TIM3) Compositions and Methods for Immunotherapy
    Publication number: 20230374456
    Abstract: Compositions and methods for editing, e.g., altering a DNA sequence, within a TIM3 gene are provided. Compositions and methods for immunotherapy are provided.
    Type: Application
    Filed: August 7, 2023
    Publication date: November 23, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventor: Danielle Ryan Cook
  • Compositions and methods for TTR gene editing and treating ATTR amyloidosis
    Patent number: 11795460
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: October 24, 2023
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Compositions and Methods for Kallikrein (KLKB1) Gene Editing
    Publication number: 20230295587
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.
    Type: Application
    Filed: August 5, 2022
    Publication date: September 21, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Shobu Odate, Jessica Lynn Seitzer
  • Modified Guide RNAs
    Publication number: 20230287400
    Abstract: This disclosure relates to modified single and dual guide RNAs having improved in vitro and in vivo activity in gene editing methods.
    Type: Application
    Filed: September 1, 2022
    Publication date: September 14, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Amy Madison Rhoden Smith, David V. Morrissey, Walter Strapps
  • Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA)
    Publication number: 20230271997
    Abstract: This disclosure relates to the field of poly-adenylated (poly-A) tails. In some embodiments, a DNA encodes a poly-A tail located 3? to nucleotides encoding a protein of interest, wherein the poly-A tail comprises one or more non-adenine nucleotide.
    Type: Application
    Filed: May 1, 2023
    Publication date: August 31, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventor: Christian Dombrowski
  • Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis
    Publication number: 20230257747
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Application
    Filed: December 9, 2022
    Publication date: August 17, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Polynucleotides, compositions, and methods for genome editing
    Patent number: 11697806
    Abstract: Compositions and methods for gene editing. In some embodiments, a polynucleotide encoding Cas9 is provided that can provide one or more of improved editing efficiency, reduced immunogenicity, or other benefits.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: July 11, 2023
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Christian Dombrowski, Jonathan Douglas Finn, Amy Madison Rhoden Smith, Seth C. Alexander
  • Compositions and Methods for Treating Alpha-1 Antitrypsin Deficiency
    Publication number: 20230212575
    Abstract: Compositions and methods for introducing double-stranded breaks within the SERPINA1 gene are provided. Compositions and methods for reducing and eliminating mutant forms of ?1-antitrypsin (AAT), such as seen in subjects having ?1-antitrypsin deficiency (AATD), are provided.
    Type: Application
    Filed: December 9, 2022
    Publication date: July 6, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Shobu Odate, Walter Strapps, Reynald Michael Lescarbeau
  • Methods of in Vitro Cell Delivery
    Publication number: 20230183753
    Abstract: Compositions and methods for multiplex delivery and gene editing in vitro are provided.
    Type: Application
    Filed: October 27, 2022
    Publication date: June 15, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Pooja Kyatsandra Narendra, Sean Michael Burns, Paula Gutierrez Martinez, Arti Mahendra Prakash Kanjolia, Anthony Monti, Aaron Prodeus, Mohamed Simo Arredouani, Özgün Kiliç, Reed Walker LaRiviere, Palak Sushil Sharma, Eleni Stampouloglou, Qingzhan Zhang
  • Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA)
    Patent number: 11673911
    Abstract: This disclosure relates to the field of poly-adenylated (poly-A) tails. In some embodiments, a DNA encodes a poly-A tail located 3? to nucleotides encoding a protein of interest, wherein the poly-A tail comprises one or more non-adenine nucleotide.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: June 13, 2023
    Assignee: Intellia Therapeutics, Inc.
    Inventor: Christian Dombrowski
  • Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis
    Publication number: 20230118592
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Application
    Filed: December 9, 2022
    Publication date: April 20, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Methods and Compositions for Directed Genome Editing
    Publication number: 20230076357
    Abstract: Provided herein are compositions and methods for increasing editing efficiency of a target nucleic acid. A composition may comprise a guide nucleic acid, a Cas9 nickase, or a reverse transcriptase. The reverse transcriptase may be fused to the Cas9 nickase. The reverse transcriptase may heterodimerize with the Cas9 nickase. The reverse transcriptase may bind to a guide nucleic acid. The reverse transcriptase may be engineered to increase processivity. The guide nucleic acid may be engineered to facilitate synthesis or editing of a sequence. The guide nucleic acid, Cas9 nickase, and reverse transcriptase may be engineered to fit within AAV vectors. The guide nucleic acid may comprise a region that binds to another region on the guide nucleic acid to improve gene editing.
    Type: Application
    Filed: May 3, 2022
    Publication date: March 9, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventor: Schaked Omer HALPERIN
  • Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent
    Publication number: 20230044994
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Application
    Filed: September 27, 2021
    Publication date: February 9, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Yong Chang, Seth C. Alexander, Kristy M. Wood, Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis Comprising a Corticosteroid or Use Thereof
    Publication number: 20230035659
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene in combination with administration of a corticosteroid are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), in which a guide RNA and a corticosteroid are administered, are provided.
    Type: Application
    Filed: September 27, 2021
    Publication date: February 2, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Yong CHANG, Seth C. ALEXANDER, Kristy M. WOOD, Arti Mahendra Prakash KANJOLIA, Shobu ODATE, Jessica Lynn SEITZER, Reynald Michael LESCARBEAU, Walter STRAPPS
  • Polynucleotides, Compositions, and Methods for Polypeptide Expression
    Publication number: 20230012687
    Abstract: Compositions and methods for gene editing. In some embodiments, a polynucleotide encoding Cas9 is provided that can provide one or more of improved editing efficiency, reduced immunogenicity, or other benefits.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 19, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Bradley Andrew Murray, Christian Dombrowski, Seth C. Alexander
  • Compositions and methods for treating alpha-1 antitrypsin deficiency
    Patent number: 11549107
    Abstract: Compositions and methods for introducing double-stranded breaks within the SERPINA1 gene are provided. Compositions and methods for reducing and eliminating mutant forms of ?1-antitrypsin (AAT), such as seen in subjects having ?1-antitrypsin deficiency (AATD), are provided.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: January 10, 2023
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Shobu Odate, Walter Strapps, Reynald Michael Lescarbeau
  • Modified Guide RNAs for Gene Editing
    Publication number: 20220372483
    Abstract: This disclosure relates to modified guide RNAs having improved in vitro and in vivo activity in gene editing methods.
    Type: Application
    Filed: June 9, 2022
    Publication date: November 24, 2022
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Seth C. Alexander, Sabin Mulepati, Matthew Roy
  • Modified guide RNAs
    Patent number: 11479767
    Abstract: This disclosure relates to modified single and dual guide RNAs having improved in vitro and in vivo activity in gene editing methods.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: October 25, 2022
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Amy Madison Rhoden Smith, David V. Morrissey, Walter Strapps